Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
<h4>Background</h4>Constitutively active androgen receptor variants (AR-V) lacking the ligand binding domain (LBD) may promote the development of castration-resistant prostate cancer (CRPC). The expression of AR-Vs in the clinically most important metastatic site, the bone, has, however,...
Guardado en:
Autores principales: | Emma Hörnberg, Erik Bovinder Ylitalo, Sead Crnalic, Henrik Antti, Pär Stattin, Anders Widmark, Anders Bergh, Pernilla Wikström |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/77576da190d54660a4133de279e53412 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
por: Giuseppe Fallara, et al.
Publicado: (2021) -
Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.
por: Rolf Gedeborg, et al.
Publicado: (2021) -
Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Richard Shore, et al.
Publicado: (2021) -
Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer
por: Govindi J. Samaranayake, et al.
Publicado: (2017) -
Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells
por: Manjul Rana, et al.
Publicado: (2021)